1-Pentan-2-yl-4-propan-2-ylpiperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-Pentan-2-yl-4-propan-2-ylpiperazine
• 英文别名: 1-pentan-2-yl-4-propan-2-ylpiperazine
• 化学式: C₁₂H₂₆N₂
• 分子量: 198.35
• InChiKey: HHMXGXVOHJVOHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient
  申请人：DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

  公开号：US10766857B2

  公开（公告）日：2020-09-08

  The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

  本发明涉及一种具有白三烯B4受体2（BLT2）抑制活性的新型化合物，以及以其为活性成分的用于预防或治疗炎症性疾病的药物组合物。本发明人发现了一种含有 BTL2 抑制活性的新型化合物，并通过实验证实本新型化合物在增强癌细胞死亡、抑制转移和趋化移动以及抗哮喘活性方面具有极佳的效果。因此，本新型化合物可用作治疗炎症相关疾病的一种非常有效的药物成分。
• NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT
  申请人：DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

  公开号：US20190071395A1

  公开（公告）日：2019-03-07

  The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.
• GLP-1R MODULATING COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20220177449A1

  公开（公告）日：2022-06-09

  The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.